Broncus Holding raises millions in latest round of financing

Broncus Holding Corp, a global leader in diagnostic and therapeutic technology for lung diseases, announced on Thursday that it has raised tens of million dollars in its Series D round of fundraising led by FountainVest Partners.

Other investors include Exome Asset Management, Summer Capital, and Valliance Capital. The new financing will be used for the commercialization and development of technology across lung cancer, emphysema and other important lung diseases.

Broncus mainly develops diagnostic and therapeutic technology for lung diseases with focus on the diagnosis of lung cancer and the treatment of emphysema. Its bronchoscopic trans-parenchymal nodule access technology, for instance, is able to access any part of the entire lung, reaching directly the lesions that are not connected to or adjacent to an airway.

Leveraging its proprietary full-lung navigation technology, the company has developed an integrated interventional pulmonology platform encompassing navigation, diagnosis and treatment.

"Our breakthrough navigation technology is enabling us to accelerate the development and commercialization of precise interventional technologies for diagnosis and treatment in order to improve options for patients with lung diseases and the physicians that care for them," said Broncus CEO Zhan Guowei

FountainVest's Managing Director Jason Li said, "FountainVest Partners is excited to be supporting Broncus, one of the leading global players in the field of interventional diagnosis and therapy of lung diseases with proven capabilities to develop cutting edge innovative medical technologies."

"Leveraging FountainVest's resource within the healthcare sector, we look forward to partnering with Broncus to explore further growth opportunities both domestically and globally," Li said.